Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use

The market for biotherapeutic monoclonal antibodies (mAbs) is large and is growing rapidly. However, attrition poses a significant challenge for the development of mAbs, and for biopharmaceuticals in general, with large associated costs in resource and animal use. Termination of candidate mAbs may o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sewell, Fiona, Chapman, Kathryn, Couch, Jessica, Dempster, Maggie, Heidel, Shawn, Loberg, Lise, Maier, Curtis, Maclachlan, Timothy K., Todd, Marque, van der Laan, Jan Willem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Meeting Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524158/
https://www.ncbi.nlm.nih.gov/pubmed/28475417
http://dx.doi.org/10.1080/19420862.2017.1324376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524158/
https://www.ncbi.nlm.nih.gov/pubmed/28475417
http://dx.doi.org/10.1080/19420862.2017.1324376

Ejemplares similares